UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Amendment No.)

Eiger BioPharmaceuticals, Inc.

(Name of Issuer)

<u>Common Stock, par value \$0.001 per share</u>
(Title of Class of Securities)

<u>28249U105</u> (CUSIP Number)

 $\frac{August\ 17,\ 2017}{\text{(Date of Event Which Requires Filing of this Statement)}}$

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□R	Rule 13d-1(b)
⊠R	Rule 13d-1(c)
□R	Rule 13d-1(d)
	inder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for uent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the *Securities Exchange Act* of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

P No. 282	49U105			13G	Page 2 of 11 Pages			
1	NAME OF REP	NAME OF REPORTING PERSONS						
	Moshe Arkin	Moshe Arkin						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠							
3	SEC USE ONLY							
4	CITIZENSHIP (OR PLACE	OF ORGANIZATION					
	Israel							
		5	SOLE VOTING POWE	ER .				
	BER OF ARES	6	SHARED VOTING PO	WER				
BENEFI	CIALLY		447,609 (*)					
	ED BY .CH	7	SOLE DISPOSITIVE POWER					
	RTING N WITH							
PERSO	N WITH	8	SHARED DISPOSITIVE POWER					
			447,609 (*)					
9	AGGREGATE A	AMOUNT	BENEFICIALLY OWNED B	Y EACH REPORTING PERSON				
	447,609 (*)							
10	CHECK IF THE	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
11	PERCENT OF C	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
	5.35% (*) (**)							
12		TYPE OF REPORTING PERSON (See instructions)						
	IN							

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,367,030 shares of Common Stock outstanding as of August 3, 2017 (as provided in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2017).

1 NAME OF REPORTING PERSONS Sphera Funds Management Ltd. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Israel 5 SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**) 12 TYPE OF REPORTING PERSON (See instructions)	P No. 2824	49U105			13G	Page 3 of 11 Pages			
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Israel 5 SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 447,609 (*) 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)	1	NAME OF RE	EPORTING P	ERSONS					
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Israel 5 SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 447,609 (*) 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)		Sphera Funds	Sphera Funds Management I td						
3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Israel	2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)							
4 CITIZENSHIP OR PLACE OF ORGANIZATION Israel									
Sole Sole	3	SEC USE ON	SEC USE ONLY						
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) Description	4	CITIZENSHIE	OR PLACE	OF ORGANIZATION					
NUMBER OF SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ Interpretation of CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)		Israel							
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			5	SOLE VOTING POV	VER				
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH									
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			6	SHARED VOTING POWER					
OWNED BY EACH REPORTING PERSON WITH 8 SHARED DISPOSITIVE POWER 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)	_	-		447 600 (*)					
PERSON WITH 8 SHARED DISPOSITIVE POWER 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)			7						
8 SHARED DISPOSITIVE POWER 447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)		_		5022 5101 60111 12	110WER				
447,609 (*) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)	PERSO	N WITH			WE BOWER				
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)			8	SHARED DISPOSIT	IVE POWER				
447,609 (*) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)				447,609 (*)					
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)	9	AGGREGATE	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
□ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)		447,609 (*)	447,609 (*)						
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)	10	CHECK IF TH	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.35% (*) (**)									
	11								
		E 3E0/ (*) (**)	[250/ (*) /**)						
1112 OF INDIONITIO LENGON (See Instructions)									
	14	TILE OF KER	OKLING PE	LIGOTA (SEE HISH UCHOHS)					

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,367,030 shares of Common Stock outstanding as of August 3, 2017 (as provided in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2017).

CUSIP No. 28249U105				13G	Page 4 of 11 Pages		
1	NAME OF REPORTING PERSONS Sphera Global Healthcare GP Ltd.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) □ (b) ⊠						
3	SEC USE ONLY						
4	CITIZENSHIP C	CITIZENSHIP OR PLACE OF ORGANIZATION Israel					
	5		SOLE VOTING PO	OWER			
NUMB SHA BENEFI OWNE	RES CIALLY	6	SHARED VOTING 447,609 (*)	ARED VOTING POWER 7,609 (*)			
EA: REPOI	CH	7	SOLE DISPOSITI	SOLE DISPOSITIVE POWER			
		8	SHARED DISPOS 447,609 (*)	ITIVE POWER			
9	AGGREGATE A 447,609 (*)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 447,609 (*)					
10	CHECK IF THE	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)					
11	PERCENT OF C 5.35% (*) (**)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	TYPE OF REPORTING PERSON (See instructions)						
	CO						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,367,030 shares of Common Stock outstanding as of August 3, 2017 (as provided in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2017).

CUSIP No. 28249U105				13G	Page 5 of 11 Pages				
1	1 NAME OF REPORTING PERSONS								
	Sphera Global Healthcare Management LP								
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)								
(a) □									
	` '	(b) ⊠							
3	3 SEC USE ONLY								
4	CITIZENSHIP	OR PLACE	OF ORGANIZATION						
	Israel								
		5	SOLE VOTING P	OWER					
NUMBE	-	6	SHARED VOTING POWER						
SHAF BENEFIC	_		447,609 (*)						
OWNE EAC		7	SOLE DISPOSITIVE POWER						
REPOR	TING								
PERSON	WITH	8	SHARED DISPOS	STEIVE DOWED					
			SHARED DISPOS	IIIVE POWER					
	1		447,609 (*)						
9	AGGREGATE .	AMOUNT I	BENEFICIALLY OWNE	ED BY EACH REPORTING PERSON					
	447,609 (*)	447,609 (*)							
10	See instructions)								
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9								
	5.35% (*) (**)								
12 TYPE OF REPORTING PERSON (See instructions)									
			(,					
СО									

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 8,367,030 shares of Common Stock outstanding as of August 3, 2017 (as provided in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2017).

Item 1. (a) <u>Name of Issuer</u>:

Eiger BioPharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306

Item 2. (a) Name of Person Filing:

Moshe Arkin

Sphera Funds Management Ltd.

Sphera Global Healthcare GP Ltd.

Sphera Global Healthcare Management LP

(b) <u>Address of Principal Business Office</u>:

Moshe Arkin – 6 Hachoshlim St., Herzelia, Israel

Sphera Funds Management Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

Sphera Global Healthcare GP Ltd. - 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

Sphera Global Healthcare Management LP – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

(c) <u>Citizenship</u>:

Moshe Arkin – Israel

Sphera Funds Management Ltd. – Israel

Sphera Global Healthcare GP Ltd. – Israel

Sphera Global Healthcare Management LP – Israel

(d) <u>Title of Class of Securities</u>:

Common Stock, par value \$0.001 per share

(e) <u>CUSIP Number</u>:

28249U105

Item 3. Not applicable.

Item 4. Ownership:

(a) <u>Amount beneficially owned:</u>

See row 9 of cover page of each reporting person.

The securities reported herein are beneficially owned as follows:

- 431,451 shares of Common Stock, representing a total of 5.16% of the total shares of Common Stock outstanding, are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management Ltd. (the "Management Company").
- 16,158 shares of Common Stock, representing a total of 0.19% of the total shares of Common Stock outstanding, are held directly by HFR HE Sphera Global Healthcare Master Trust, which has delegated its investment management authority to the Management Company.

The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., which is controlled jointly by Sphera Funds Management Ltd. and Moshe Arkin.

This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.

(b) Percent of class:

See row 11 of cover page of each reporting person

- (c) <u>Number of shares as to which such person has:</u>
 - (i) Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

Shared power to dispose or to direct the disposition of: (iv) See row 8 of cover page of each reporting person and note in Item 4(a) above Item 5. Ownership of Five Percent or Less of a Class: Not applicable. Ownership of More than Five Percent on Behalf of Another: Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Not applicable. <u>Identification and Classification of Members of the Group</u>: Item 8. Not applicable. Item 9. Notice of Dissolution of Group: Not applicable.

8

Item 10. <u>Certification</u>:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 22, 2017

Moshe Arkin

/s/ Moshe Arkin

By: Moshe Arkin

Sphera Funds Management Ltd.

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer

Sphera Global Healthcare GP Ltd.

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer

Sphera Global Healthcare Management LP

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer

EXHIBIT NO. DESCRIPTION

Exhibit 1 Joint Filing Agreement by and among the Reporting Persons, dated as of August 22, 2017.

Exhibit 1

Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Eiger BioPharmaceuticals, Inc. Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. In accordance with Rule 13d-1(k)(1), the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G and any amendments thereto with respect to the equity securities (as defined in Rule 13d-1(i)) of the Issuer, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13G and any amendments thereto.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

August 22, 2017

Moshe Arkin

/s/ Moshe Arkin

By: Moshe Arkin

Sphera Funds Management Ltd.

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer

Sphera Global Healthcare GP Ltd.

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer

Sphera Global Healthcare Management LP

/s/ Ori Goldfarb

By: Ori Goldfarb

Title: Chief Executive Officer